Multigene assay as a prognostic and predictive tool for chemotherapy treatment in Early breast cancer

Authors

  • Pavinee Annoppornchai Division of Plastic surgery, Department of surgery, King Chulalongkorn Memorial Hospital, Thai Red Cross Society
  • Jathurong Kittrakulrat Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society
  • Adhisabandh Chulakadabba Queen Sirikit Center for Breast Cancer, King Chulalongkorn Memorial Hospital, Thai Red Cross Society
  • Kanjana Shotelersuk Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University

Keywords:

Multigene assay, Early breast cancer, chemotherapy

Abstract

Treatment of ER+ HER2- early breast cancer composes not only surgery, radiation and hormonal therapy, but also chemotherapy. Weighing side effect versus benefit of chemotherapy should be considered. In the past, decision was made from clinicopathological risk factors. Nowadays, gene expression assays can represent chemotherapy benefit in individual tumor and can be used to determine if chemotherapy should be given or not. Even though all multigene assays reflect risk of recurrence, they differ substantially in the technological platform, i.e. the number and identity of genes assessed, the patient populations that were used for development and validation, and the level of evidence supporting clinical utility. These differences could impact physicians’ decision regarding to cost-effectiveness in different scenarios.

References

National Cancer Institute. Hospital-based cancer registry. Bangkok: Porsup Printing; 2018.

American Cancer Society. Chemotherapy for breast cancer [Internet].2019 [cited 2019 Nov 15]. Available from: https://www.cancer.org/cancer/breast-cancer/treatment/chemotherapy-for-breast-cancer.html#references.

Balic M, Thomssen C, Würstlein R, Gnant M, Harbeck N. St. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care 2019;14:1-8.

Gnant M, Harbeck N, Thomssen C. St. Gallen/Vienna 2017: A brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. Breast Care (Basel) 2017;12:102-7.

Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, et al. NCCN Guidelines insights: Breast cancer, Version 3.2018. J Natl Compr Canc Netw 2019;17:118-26.

Henry NL, Somerfield MR, Abramson VG, Ismaila N, Allison KH, Anders CK, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: update of the ASCO endorsement of the Cancer Care Ontario Guideline. J Clin Oncol 2019;37:1965-77.

Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, et al. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technol Assess 2019;23:1-328.

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1674.

Shalon D, Smith SJ, Brown PO. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 1996;6:639-45.

Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70.

Huggett J, Dheda K, Bustin S, Zumla A. Real-time RT-PCR normalisation; strategies and considerations. Genes Immun 2005;6:279.

Bustin S, Benes V, Nolan T, Pfaffl M. Quantitative real-time RT-PCR–a perspective. J Mol Endocrinol 2005;34:597-601.

Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protoc 2006;1:1559.

Genomic Health. Oncotype DX [Internet]. 2019 [cited 2019 Oct 10]. Avilable from: https://www.oncotypeiq.com/en-US/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/about-the-test.

Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677-83.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111-21.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat 2017;165:573-83.

Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829-34.

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer 2016;2:16017.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-Gene expression assay in breast cancer. N Engl J Med 2015;373:2005-14.

Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, et al. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol 2019.

van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.

Agendia. MammaPrint [Internet]. 2019 [cited 2019 Oct 11]. Avilable from: https://www.agendia.com/our-tests/mammaprint.

Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.

Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92.

Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FSAM, Karsenberg K, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007;8:1079-87.

Van De Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375:717-29.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.

Nanostring. Prosigna [Internet]. 2018 [cited 2019 Oct 11]. Avilable from: https://www.nanostring.com/diagnostics/prosigna-uk.

Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 2014;20:1298-305.

Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013;31:2783-90.

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014;25:339-45.

Myriad Genetic Laboratories. EndoPredict [Internet]. 2019 [cited 2019 Oct 11]. Avilable from: https://endopredict.com.

Muller BM, Brase JC, Haufe F, Weber KE, Budzies J, Petry C, et al. Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. J Clin Pathol 2012;65:660-2.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011;17:6012-20.

Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, et al. Prediction of distant recurrence using EndoPredict among women with ER(+), HER2(-) Node-positive and Node-negative breast cancer treated with endocrine therapy only. Clin Cancer Res 2019;25:3865-72.

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 2013;24:640-7.

Sestak I, Martin M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat 2019;176:377-86.

Mlakar V, Glavac D. DNA microarrays and their use in dermatology. Acta Dermatoven APA 2007;16:7.

Downloads

Published

2020-07-30

How to Cite

1.
Annoppornchai P, Kittrakulrat J, Chulakadabba A, Shotelersuk K. Multigene assay as a prognostic and predictive tool for chemotherapy treatment in Early breast cancer. J Thai Assn of Radiat Oncol [Internet]. 2020 Jul. 30 [cited 2024 Mar. 29];26(2):O1-O18. Available from: https://he01.tci-thaijo.org/index.php/jtaro/article/view/240127

Issue

Section

Review articles